Mifamurtide

DRUG5 trials

Sponsors

Instytut Matki I Dziecka, Millennium Pharmaceuticals, Inc., University of Oxford, UNICANCER, Anna Raciborska

Conditions

High-grade osteosarcomaOsteosarcomaRelapsed/refractory osteosarcoma

Phase 2

A Eurosarc Study of Mifamurtide in Advanced Osteosarcoma (MEMOS)

TerminatedNCT02441309

University of OxfordOsteosarcoma

Start: 2014-10-31End: 2016-11-04Updated: 2019-09-13

Mifamurtide Combined With Post-operative Chemotherapy for Newly Diagnosed High Risk Osteosarcoma Patients

Active, not recruitingNCT03643133

UNICANCEROsteosarcoma

Start: 2018-10-23End: 2033-10-01Updated: 2026-05-19

A randomized phase II study comparing the safety and efficacy of mifamurtide and standard therapy containing sorafenib in pediatric and young adult patients with high-risk osteosarcoma

Not yet recruitingCTIS2026-525223-24-00

Instytut Matki I DzieckaHigh-grade osteosarcoma, Relapsed/refractory osteosarcoma

Target: 40Updated: 2026-04-20

Evaluation of the Safety and Efficacy of Mifamurtide Versus Standard Treatment With Sorafenib in Patients With High-risk Osteosarcoma

RecruitingNCT07787429

Anna RaciborskaOsteosarcoma

Start: 2026-04-01End: 2033-07-31Target: 40Updated: 2026-08-26

Unknown Phase

Surveillance Study of Patients With Newly Diagnosed Osteosarcoma

TerminatedNCT01194284

Millennium Pharmaceuticals, Inc.Osteosarcoma

Start: 2011-12-31End: 2013-12-31Updated: 2017-01-19

Related Papers

Sarcome-13/OS2016 trial protocol: a multicentre, randomised, open-label, phase II trial of mifamurtide combined with postoperative chemotherapy for patients with newly diagnosed high-risk osteosarcoma

BMJ Open2019-05-0137 citations